文献速递冠心病

ST段抬高型心肌梗死患者长期死亡率与院前替罗非班治疗

Long-term mortality and prehospital tirofiban treatment in patients with ST elevation myocardial infarction.
PubMed 文献 · Heart · 2017-07-05

该研究为On-TIME 2试验的事后亚组分析,纳入984例接受直接PCI的STEMI患者,随机接受院前替罗非班或安慰剂。基线NT-proBNP高于中位数(137 pg/mL)是5年死亡率的独立预测因子(HR 2.73,95%CI 1.47-5.06;p=0.002)。在NT-proBNP高于中位数的患者中,早期替罗非班治疗显著降低30天和1年死亡率,5年死亡率降低但无统计学意义。

要点

  • 基线NT-proBNP高于中位数独立预测STEMI患者5年死亡率。
  • NT-proBNP高于中位数者接受院前替罗非班可降低30天和1年死亡率。
  • 5年死亡率在替罗非班组较低但无统计学意义,需其他研究证实。

核心结论

  • 在STEMI患者中,基线NT-proBNP水平独立预测长期死亡率。
  • 基线NT-proBNP高于中位数的患者,院前早期替罗非班治疗显著降低30天和1年死亡率,提示高危患者可能获益更多,但需其他研究证实。

研究设计与样本

  • On-TIME 2试验的亚组分析,为安慰剂对照、双盲、随机试验。
  • 共纳入984例接受直接PCI的STEMI患者,随机分为救护车内替罗非班组或安慰剂组。
  • 基线(入院造影前)918例(93.3%)有NT-proBNP值,PCI后18-96小时865例(87.9%)有NT-proBNP值。

主要发现

  • 基线NT-proBNP高于中位数(137 pg/mL)的患者30天死亡率5.1% vs 0.2%(p<0.001),1年死亡率7.0% vs 0.7%(p<0.001),5年死亡率20.3% vs 4.9%(p<0.001)。
  • 多因素Cox分析显示,NT-proBNP高于中位数是5年死亡率的独立预测因子(HR 2.73,95%CI 1.47-5.06;p=0.002)。
  • NT-proBNP高于中位数的患者中,替罗非班组30天死亡率2.7% vs 安慰剂组7.5%(p=0.021),1年死亡率4.5% vs 9.4%(p=0.043)。
  • 5年时治疗组死亡率较低但无统计学意义(18% vs 22.4%,p=0.265)。

临床怎么用

  • 对STEMI患者可检测基线NT-proBNP以辅助长期风险分层。
  • 基线NT-proBNP高于中位数的患者,院前早期使用替罗非班可能改善30天和1年生存。

局限性

  • 研究为On-TIME 2试验的亚组分析,结果需在其他研究中证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We undertook a subgroup analysis of the On-TIME 2 (Ongoing Tirofiban In Myocardial infarction Evaluation 2), a placebo-controlled, double-blind, randomised trial, in order to evaluate the association between N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels and long-term (5 years) mortality and to investigate the effect of prehospital tirofiban administration on mortality in relation to NT-proBNP levels. METHODS: A total of 984 patients with ST elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) were randomised to either in ambulance tirofiban or placebo. NT-proBNP levels were evaluated on admission before angiography (baseline) and 18-96 hours thereafter (post PCI). RESULTS: There were 918 (93.3%) patients with NT-proBNP values available at baseline and 865 (87.9%) post PCI. Patients with baseline NT-proBNP values above the median (137 pg/mL) had higher 30-day (5.1% vs 0.2%, p<0.001), 1-year (7.0% vs 0.7%, p<0.001) and 5-year (20.3% vs 4.9%, p<0.001) mortality as compared with patients with values below the median. Using multivariate Cox analysis, NT-proBNP above the median was an independent predictor for 5-year mortality (HR 2.73, 95% CI 1.47 to 5.06; p=0.002). Patients with values above the median who received early tirofiban treatment had significant lower mortality compared with patients treated with placebo at 30 days (2.7% vs 7.5%, p=0.021) and 1 year (4.5% vs 9.4%, p=0.043). At 5 years, a lower but non-significant mortality rate was maintained in the treatment group (18% vs 22.4%, p=0.265). CONCLUSIONS: In patients with STEMI, baseline NT-proBNP level independently predicts long-term mortality. In patients with baseline NT-proBNP levels above the median, early prehospital treatment with tirofiban significantly reduced 30-day and 1-year mortality, suggesting that high-risk patients may derive particular benefit. This finding should be confirmed in other studies. TRIAL REGISTRATION NUMBER: ISRCTN06195297.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Fabris E, Kilic S, Schellings DAAM, et al. Long-term mortality and prehospital tirofiban treatment in patients with ST elevation myocardial infarction. Heart. 2017. PMID: 28679686. doi:10.1136/heartjnl-2017-311181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。